The recently identified epidermal growth factor-related peptide cripto-1 has been previously implicated in the development of the malignant phenotype. The identification of gene products that can act as prognostic markers in @entity150 would be value in determining the management of this heterogeneous group of @entity1 . This study examines cripto-1 expression in benign and malignant bladder using immunohistochemical techniques. The expression of cripto-1 protein in benign and malignant bladder was examined in 45 @entity150 (Ta/T1 n = 26, T2 n = 5, T3/T4 n = 14) and six benign controls. All 45 @entity5 showed positive cytoplasmic staining for cripto-1, including areas of @entity189 in situ. None of the six benign controls showed any evidence of positive cripto-1 staining. Twenty-three (60 per cent) @entity150 had areas of @entity5 that showed strong positive staining for cripto-1 as opposed to six (29 per cent) sections of histologically normal urothelium adjacent to @entity5 (P < 0.05). There was no association between cripto-1 staining and @entity5 grade, stage, or clinical outcome. Cripto-1 protein appears to be specifically expressed in malignant and benign adjacent urothelium of @entity1 with @entity150 . Its clinical significance, however, remains to be determined.

The immunohistochemical detection of cripto-1 in benign and malignant XXXX bladder.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma'] @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder cancer', 'bladder tumours'] @entity5 :: ('MESH:D009369', 'Disease') :: ['papillary tumour', 'tumours', 'tumour']
@entity1 :: (9606,Species) :: ['human']
